SINOVAC is committed to developing and innovating cutting-edge vaccines to meet the challenge of preventing human diseases worldwide.
SINOVAC upholds a diversified product pipeline and a continuous process of innovation to support its aims to develop safer and more effective vaccines that provide protection from disease for all people, everywhere.
SINOVAC has undertaken nearly 60 national and regional science and technology R&D projects; received two State Scientific and Technology Progress Awards and three national-level institutional technology awards; and published more than 140 SCI papers.
SINOVAC has built close ties with global top universities and scientific research institutions, and continually dedicates itself to new vaccine R&D.